CART-33 (Chinese PLA General Hospital)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCART-33 (Chinese PLA General Hospital)
Drug Alias Nameanti-CD33 CAR T-cell therapy (leukemia)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia, Myeloid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsLeukemia, Myeloid

Other Information

ATC CodeN/A
Related LinksN/A